ALNY Key Statistics, Chart & Performance
The current stock price of ALNY is 415.21 USD. In the past month the price decreased by -6%. In the past year, price increased by 69.17%.
ALNY Latest News, Press Relases and Analysis
ALNY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.6 | 394.11B | ||
| AMGN | AMGEN INC | 14.35 | 169.00B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 148.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 110.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.39 | 72.79B | ||
| INSM | INSMED INC | N/A | 41.41B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.5 | 25.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 15.04B |
Related stock screener links
About ALNY
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS 02142 US
CEO: John M. Maraganore
Employees: 2230
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you describe the business of ALNYLAM PHARMACEUTICALS INC?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
What is the stock price of ALNYLAM PHARMACEUTICALS INC today?
The current stock price of ALNY is 415.21 USD. The price decreased by -3.44% in the last trading session.
Does ALNYLAM PHARMACEUTICALS INC pay dividends?
ALNY does not pay a dividend.
What is the ChartMill rating of ALNYLAM PHARMACEUTICALS INC stock?
ALNY has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of ALNYLAM PHARMACEUTICALS INC (ALNY) based on its PE ratio?
The PE ratio for ALNYLAM PHARMACEUTICALS INC (ALNY) is 814.14. This is based on the reported non-GAAP earnings per share of 0.51 and the current share price of 415.21 USD.
Can you provide the growth outlook for ALNYLAM PHARMACEUTICALS INC?
The Revenue of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 67.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ALNYLAM PHARMACEUTICALS INC?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 54.85B USD. This makes ALNY a Large Cap stock.
ALNY Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY is one of the better performing stocks in the market, outperforming 88.66% of all stocks.
ALNY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALNY. ALNY has an average financial health and profitability rating.
ALNY Financial Highlights
Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 119.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.36% | ||
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| Debt/Equity | 4.45 |
ALNY Forecast & Estimates
37 analysts have analysed ALNY and the average price target is 495.92 USD. This implies a price increase of 19.44% is expected in the next year compared to the current price of 415.21.
For the next year, analysts expect an EPS growth of 186.28% and a revenue growth 67.16% for ALNY